Pancreatic Cancer Research

ResearcherUniversity of CopenhagenActive in the last 2 years

Brett C. Sheppard

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2182-7547; OpenAlex author ID A5043127162; NIH RePORTER profile ID 9455202. Sources: ClinicalTrials.gov.

Their work

Papers
34 (first author 1, last author 4)
Trials
1 (principal investigator on 1)
Grants
2
Labs led
1
Collaborators
90
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper, 1 grant · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 5 papers · 2023: 6 papers · 2024: 7 papers · 2025: 5 papers · 2026: 3 papers, 1 trial, 1 grant

Papers 34

  1. Addressing pancreatic cancer disparities in Oregon's Native American population via tribally responsive research systems with the confederated tribes of warm s… Co-author DOI 10.1007/s10552-026-02148-x↗
  2. Surveillance for Pancreatic Cancer: Knowledge, Motivations, Barriers, and Preferences Among High-Risk Individuals and Underserved Populations. Co-author DOI 10.1177/10732748261468819↗
  3. Epigenetic progression of pancreatic cancer to aggressive subtypes involves alternate routes of lineage reprogramming in subtype-intermediate progenitor cells Co-author DOI 10.64898/2026.09.28.754674↗
  4. Protocol to purify and culture human pancreatic cancer cells from patient-derived xenografts. Co-author DOI 10.1016/j.xpro.2025.103672↗
  5. Ongoing replication stress tolerance and clonal T cell responses distinguish liver and lung recurrence and outcomes in pancreatic cancer. Co-author DOI 10.1038/s43018-024-00881-3↗
  6. Long Noncoding RNAs Preserve Pancreatic Cancer Identity and Resist Cell Fate Conversion Co-author DOI 10.1101/2025.06.25.661419↗
  7. Early detection of pancreatic cancer by a high-throughput protease-activated nanosensor assay. Co-author DOI 10.1126/scitranslmed.adq3110↗
  8. The Prolyl Isomerase PIN1 Affects Fibroblast Differentiation States and Cross-talk in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-24-3437↗
  9. Sendai virus is robust and consistent in delivering genes into human pancreatic cancer cells. Co-author DOI 10.1016/j.heliyon.2024.e27221↗
  10. Rapid metastatic recurrence after pancreatic cancer resection: a multi-center, regional analysis of trends in surgical failure over two decades. Co-author DOI 10.1016/j.hpb.2024.08.006↗
  11. CASPER: A Phase I trial combining calaspargase pegol-mnkl and cobimetinib in pancreatic cancer. Co-author DOI 10.1080/14796694.2024.2395235↗
  12. A high throughput blood-based assay for the early detection of pancreatic cancer Co-author DOI 10.1101/2024.01.12.24301220↗
  13. The Legacy of Jeff Norton: From Cachexia to the Earlier Detection of Pancreatic Cancer 36 Years of Mentoring a Surgical Scientist. Co-author DOI 10.1245/s10434-024-15218-8↗
  14. Circulating Neoplastic-Immune Hybrid Cells Are Biomarkers of Occult Metastasis and Treatment Response in Pancreatic Cancer. Co-author DOI 10.3390/cancers16213650↗
  15. Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency. Co-author DOI 10.3791/65811↗
  16. Socioeconomic and Geographic Disparities in the Referral and Treatment of Pancreatic Cancer at High-Volume Centers. Last author DOI 10.1001/jamasurg.2022.6709↗
  17. Phase 2 study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic… Co-author DOI 10.1002/cam4.5971↗
  18. Neoadjuvant therapy does not impact the biliary microbiome in patients with pancreatic cancer. Last author DOI 10.1002/jso.27281↗
  19. High-volume centers are associated with higher receipt of combined therapy in stage III pancreatic cancer. Last author DOI 10.1016/j.amjsurg.2023.02.012↗
  20. Development of a blood-based extracellular vesicle classifier for detection of early-stage pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s43856-023-00351-4↗
  21. Micelle-Formulated Juglone Effectively Targets Pancreatic Cancer and Remodels the Tumor Microenvironment. Co-author DOI 10.3390/pharmaceutics15122651↗
  22. Disparities in pancreatic cancer care and research in Native Americans: Righting a history of wrongs. Last author DOI 10.1002/cncr.34118↗
  23. The patient's perspective: a qualitative study of individual experience with decision-making, treatment, and recovery for resectable pancreatic cancer. Co-author DOI 10.1007/s00520-021-06690-z↗
  24. Validation of automated body composition analysis using diagnostic computed tomography imaging in patients with pancreatic cancer. Co-author DOI 10.1016/j.amjsurg.2022.03.025↗
  25. Neoadjuvant Therapy Is Associated with Improved Chemotherapy Delivery and Overall Survival Compared to Upfront Resection in Pancreatic Cancer without Increasin… Co-author DOI 10.3390/cancers14030609↗
  26. Microfluidics Formulated Liposomes of Hypoxia Activated Prodrug for Treatment of Pancreatic Cancer. Co-author DOI 10.3390/pharmaceutics14040713↗
  27. Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. Co-author DOI 10.1158/2159-8290.cd-20-0841↗
  28. Hypoxia: Friend or Foe for drug delivery in Pancreatic Cancer. First author DOI 10.1016/j.canlet.2020.07.041↗
  29. Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-18-0717↗
  30. Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer. Co-author DOI 10.1200/jco.2017.77.6658↗
  31. MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance. Co-author DOI 10.1038/s41467-017-01967-6↗
  32. Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer. Co-author DOI 10.1158/1541-7786.mcr-13-0542↗
  33. Human pancreatic cancer fusion 2 (HPC2) 1-B3: a novel monoclonal antibody to screen for pancreatic ductal dysplasia. Co-author DOI 10.1002/cncy.21223↗
  34. The novel monoclonal antibody HPC2 and N-cadherin distinguish pancreatic ductal adenocarcinoma from cholangiocarcinoma. Co-author DOI 10.1016/j.humpath.2011.11.012↗

Trials 1

  1. A Surgical Procedure (Total Pancreatectomy) With a Transplant Procedure (Islet Cell Autotransplantation) for the Treatment of Chronic Pancreatitis and Benign P… Principal investigator NCT05453851↗

Grants 2

  1. Validation of novel imaging and molecular tests for early detection of pancreatic cancer through risk-stratified community engagement programs U01CA278923↗
  2. Blood-based and Imaging Biomarkers of PDAC in New-onset Diabetics AWARD pancan:2017-brett-sheppard-rosalie-sears-blood-based-and-imaging-biomarkers-of-pd

Closest collaborators

The 25 strongest of 90 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rosalie C. Sears · 20 shared papers, 1 shared grant, 2014–2026 · strength 4.10
  2. Charles D. Lopez · 11 shared papers, 2014–2025 · strength 1.62
  3. Alexander Savio Ramos Guimaraes · 3 shared papers, 1 shared grant, 2024–2026 · strength 1.47
  4. Jason M. Link · 8 shared papers, 2017–2026 · strength 1.31
  5. Thomas Lee Sutton · 7 shared papers, 2022–2024 · strength 1.25
  6. Gregory A. Coté · 1 shared paper, 1 shared grant, 2026 · strength 1.16
  7. Ranish K. Patel · 6 shared papers, 2023–2025 · strength 1.15
  8. Skye C. Mayo · 6 shared papers, 2022–2024 · strength 0.98
  9. Jonathan Robert Brody · 5 shared papers, 2022–2026 · strength 0.97
  10. Brittany L. Allen-Petersen · 7 shared papers, 2014–2025 · strength 0.89
  11. Dmytro Grygoryev · 4 shared papers, 2024–2025 · strength 0.84
  12. Jungsun Kim · 4 shared papers, 2024–2025 · strength 0.84
  13. Terry K. Morgan · 6 shared papers, 2012–2025 · strength 0.83
  14. Jackilen Shannon · 3 shared papers, 2022–2026 · strength 0.82
  15. Aaron J. Grossberg · 5 shared papers, 2022–2023 · strength 0.79
  16. Adel Kardosh · 5 shared papers, 2022–2025 · strength 0.75
  17. Motoyuki Tsuda · 4 shared papers, 2023–2026 · strength 0.72
  18. Ellen M. Langer · 4 shared papers, 2023–2026 · strength 0.72
  19. Patrick Joseph Worth · 4 shared papers, 2017–2026 · strength 0.67
  20. Vidhi M. Shah · 4 shared papers, 2020–2025 · strength 0.62
  21. Kevin Hawthorne · 3 shared papers, 2025–2026 · strength 0.57
  22. Melissa H. Wong · 3 shared papers, 2024–2025 · strength 0.57
  23. Claymore Kills First · 2 shared papers, 2022–2026 · strength 0.52
  24. Gordon Brent Mills · 3 shared papers, 2024–2025 · strength 0.48
  25. Adam W. G. Alani · 3 shared papers, 2020–2023 · strength 0.46

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.